We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

Pioglitazone Use and Risk of Bladder Cancer

Benjamin J. Davies, MD1
[+] Author Affiliations
1Department of Urology, University of Pittsburgh, Pittsburgh, Pennsylvania
JAMA. 2015;314(23):2568. doi:10.1001/jama.2015.13909.
Text Size: A A A
Published online


To the Editor A prospective cohort study1 found no relationship between pioglitazone use and the development of bladder cancer, with a median follow-up of 6.1 years. The results are in contrast to the interim 5-year analysis of the study. The new result was not surprising given that the study design favored the null hypothesis.

First, the study excluded any person developing bladder cancer within 6 months of entry into the cohort. A meta-analysis of clinical trials performed by Takeda found that a significant number of patients get bladder cancer in less than 6 months’ duration of pioglitazone use.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




December 15, 2015
Assiamira Ferrara, MD, PhD; James D. Lewis, MD, MSCE; Laurel A. Habel, PhD
1Division of Research, Kaiser Permanente Northern California, Oakland, California
2Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia
JAMA. 2015;314(23):2568-2569. doi:10.1001/jama.2015.13915.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...